Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.

Original languageEnglish (US)
Pages (from-to)46-50
Number of pages5
JournalGynecologic oncology
Volume144
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Topotecan
Neuroendocrine Carcinoma
Small Cell Carcinoma
Paclitaxel
Cervix Uteri
Disease-Free Survival
Therapeutics
Bevacizumab
Drug Therapy
Survival

Keywords

  • Cervical cancer
  • Neuroendocrine
  • Small cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

@article{1476317e67564f8aaf46a159d292059d,
title = "Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix",
abstract = "Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95{\%} CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95{\%} CI 0.23–1.22, P = 0.13). Eight women (62{\%}) who received TPB versus four (19{\%}) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31{\%}) in the TPB group versus two (10{\%}) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23{\%}) had complete response, two (15{\%}) had complete response outside the brain with progression in the brain, 3 (23{\%}) had a partial response, 2 (15{\%}) had stable disease, and 3 (23{\%}) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.",
keywords = "Cervical cancer, Neuroendocrine, Small cell carcinoma",
author = "Michael Frumovitz and Munsell, {M. F.} and Burzawa, {Jennifer Kelly} and Byers, {Lauren Averett} and Preetha Ramalingam and J. Brown and Robert Coleman",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2016.10.040",
language = "English (US)",
volume = "144",
pages = "46--50",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix

AU - Frumovitz, Michael

AU - Munsell, M. F.

AU - Burzawa, Jennifer Kelly

AU - Byers, Lauren Averett

AU - Ramalingam, Preetha

AU - Brown, J.

AU - Coleman, Robert

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.

AB - Objectives To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. Methods We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Results Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8 months for TPB and 4.0 months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P = 0.001). Median overall survival (OS) was 9.7 months for TPB and 9.4 months for non-TPB regimens (HR 0.53, 95% CI 0.23–1.22, P = 0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for > 6 months (P = 0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for > 12 months (P = 0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. Conclusions These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.

KW - Cervical cancer

KW - Neuroendocrine

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85006106381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006106381&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.10.040

DO - 10.1016/j.ygyno.2016.10.040

M3 - Article

C2 - 27823771

AN - SCOPUS:85006106381

VL - 144

SP - 46

EP - 50

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -